Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  paclitaxel albumin-stabilized nanoparticle formulation
Find trials that include:  Any drugs shown
Results 1-25 of 89 for your search:
Start Over
Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly
Status: Active
Phase: Phase IV
Type: Treatment
Age: 70 and over
Trial IDs: ABI-007-NSCL-005, NCI-2014-02488, NCT02151149
Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)
Status: Active
Phase: Phase III, Phase II
Type: Treatment
Age: 18 and over
Trial IDs: PCYC-1137-CA, NCI-2015-01722, NCT02436668
Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: ABI-007-NSCL-003, NCI-2014-01528, 2014-003804-66, NCT02027428
A Phase III Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Nab-Paclitaxel in Patients With Non-Squamous Non-Small Cell Lung Cancer [IMpower 130]
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: GO29537, NCI-2015-01602, 2014-003206-32, NCT02367781
Romidepsin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients with Metastatic Inflammatory Breast Cancer
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Treatment
Age: Over 18
Trial IDs: 13C.387, NCI-2013-01695, 080-38270-J94401, 2013-35, NCT01938833
To Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 6 months to 21 years
Trial IDs: ABI-007-PST-001, NCI-2015-00737, NCT01962103
Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NLG2104, NCI-2014-02095, NCT02077881
Selinexor, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients with Metastatic Pancreatic Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: 2013-133, NCI-2014-01249, 1403012942, NCT02178436
A Phase 1/2 Trial of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 as Neoadjuvant Chemotherapy in Locally Advanced, Unresectable Pancreatic Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: FGCL-3019-069, NCI-2015-01207, NCT02210559
Multi-tracer PET/CT in Predicting and Assessing Response in Patients with Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer Receiving Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Age: 18 and over
Trial IDs: HCI74163, NCI-2014-02370, 74163, NCI-2014-02286, NCT02245217
Genetic Analysis-Guided Dosing of FOLFIRABAX in Treating Patients with Advanced Gastrointestinal Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: IRB14-0595, NCI-2014-02407, NCT02333188
PI3K Inhibitor BYL719 and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients with HER-2 Negative Stage III or IV Breast Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CBYL719XUS06T, NCI-2015-00802, STUDY00001632, NCT02379247
A Study of Gemcitabine and Nab-paclitaxel With or Without NPC-1C to Treat Patients With Pancreatic Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: PB1201, NCI-2013-01411, NCT01834235
Durvalumab and Combination Chemotherapy in Treating Patients with Stage I-III Triple Negative Breast Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 1409014537, NCI-2016-00070, ESR-14-10265, NCT02489448
Study of 5-fluorouracil (5-FU), Nab-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 65
Trial IDs: ABI-007-PANC-009, NCI-2016-00214, NCT02620800
Bispecific Antibody Armed Activated T-cells with Aldesleukin and Sargramostim in Treating Patients with Locally Advanced or Metastatic Pancreatic Cancer
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2015-100, NCI-2015-01942, 1510014428, NCT02620865
Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: D4198C00003, NCI-2016-00470, NCT02583477
A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CA209-370, NCI-2016-00707, NCT02574078
Study to Evaluate CORT125134 in Combination With Nab-paclitaxel in Patients With Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CORT125134-550, NCI-2016-00733, NCT02762981
Carboplatin, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, and Bevacizumab or Trastuzumab Before Surgery in Treating Women With Stage I-III Breast Cancer
Status: Temporarily closed
Phase: Phase II
Type: Treatment
Age: 21 to 90
Trial IDs: UCI-07-61, NCI-2010-00155, 2007-6084, NCT00618657
GSK1120212 Rollover Study
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 114375, NCI-2011-03211, NCT01376310
Start Over